Abstract
Introduction: Maintaining adherence to antiretroviral therapy (ART) is critical to achieve and sustain viral suppression in HIV-infected patients.
Aim: To assess adherence and treatment outcomes during the implementation of ART.
Methods: A cross-sectional study was performed in adult HIV-infected patients receiving ART for at least 6 months in a teaching hospital in Surabaya, Indonesia. The Indonesian version of the validated self-reported adherence (SERAD) questionnaire was used to recall ART use during the last week, month, and three months. Logistic regression analysis was used to identify factors affecting adherence and treatment outcomes (HIV-1 RNA viral load ≤1000 copies/mL and CD4 >200 cells/µL) with pResults: Ninety five patients (male: 70.5%; duration of ART >24 months: 57.9%) completed the study. Viral suppression and improved CD4 were observed in 83.2% and 68.4% of the subjects, respectively. An adherence rate of ≥95% was considered highly adherent and observed in 89.5%, 88.4%, 95.8% of the subjects in the past week, month, and three months, respectively. WHO clinical stage III or IV and low adherence were significantly associated with detectable viral load and low CD4; ≥95% adherence rate was needed to achieve the outcomes. Forgetfulness and falling asleep were the most common reasons reported for missing doses or not respecting intake conditions.
Conclusion: Self-report is useful to assess adherence and reasons for nonadherence; large scale studies are needed to evaluate the validity of the adherence threshold in this population.
Aim: To assess adherence and treatment outcomes during the implementation of ART.
Methods: A cross-sectional study was performed in adult HIV-infected patients receiving ART for at least 6 months in a teaching hospital in Surabaya, Indonesia. The Indonesian version of the validated self-reported adherence (SERAD) questionnaire was used to recall ART use during the last week, month, and three months. Logistic regression analysis was used to identify factors affecting adherence and treatment outcomes (HIV-1 RNA viral load ≤1000 copies/mL and CD4 >200 cells/µL) with pResults: Ninety five patients (male: 70.5%; duration of ART >24 months: 57.9%) completed the study. Viral suppression and improved CD4 were observed in 83.2% and 68.4% of the subjects, respectively. An adherence rate of ≥95% was considered highly adherent and observed in 89.5%, 88.4%, 95.8% of the subjects in the past week, month, and three months, respectively. WHO clinical stage III or IV and low adherence were significantly associated with detectable viral load and low CD4; ≥95% adherence rate was needed to achieve the outcomes. Forgetfulness and falling asleep were the most common reasons reported for missing doses or not respecting intake conditions.
Conclusion: Self-report is useful to assess adherence and reasons for nonadherence; large scale studies are needed to evaluate the validity of the adherence threshold in this population.
| Original language | English |
|---|---|
| Pages (from-to) | 5-5 |
| Number of pages | 31 |
| Journal | International Journal of Clinical Pharmacy |
| DOIs | |
| Publication status | Published - 1-Feb-2023 |